Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma

• Published in: European journal of surgical oncology 2007-09, Vol.33 (7), p.843-848
• Main Authors: Koo, D.H, Lee, J.L, Kim, T.W, Chang, H.M, Ryu, M.H, Yook, J.H, Oh, S.T, Kim, B.S, Lee, J.S, Kang, Y.K
• Format: Article
• Language: English
• Subjects: 5-fluorouracil; Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Adenocarcinoma - surgery; Adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Doxorubicin - administration & dosage; Doxorubicin - therapeutic use; Female; Fluorouracil - administration & dosage; Fluorouracil - therapeutic use; Follow-Up Studies; Gastrectomy - methods; Gastric carcinoma; Hematology, Oncology and Palliative Medicine; Humans; Incidence; Korea - epidemiology; Male; Middle Aged; Mitomycin - administration & dosage; Mitomycin - therapeutic use; Mitomycin-C; Neoplasm Recurrence, Local - epidemiology; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Stomach Neoplasms - surgery; Surgery; Survival Rate - trends; Time Factors; Treatment Outcome
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2006.11.030

Abstract Aim This study aimed to evaluate the efficacy and safety of 5-fluorouracil (5-FU), doxorubicin and mitomycin-C (FAM) adjuvant chemotherapy in patients who had undergone curative resection of gastric carcinoma. Methods From Nov 1999 to Jan 2002, 291 consecutive patients with stage IB–IIIB gastric adenocarcinoma were given FAM adjuvant chemotherapy. Chemotherapy comprised intravenous 5-FU 600 mg/m2 (days 1, 8, 29 and 36), doxorubicin 30 mg/m2 (days 1 and 29) and mitomycin-C 10 mg/m2 (day 1), every 8 weeks for 6 months. Results The median follow-up time was 60.6 months, 92 patients died, and 93 patients had recurrent disease. The 5-year overall survival (OS) rates were 85.9% for stage IB, 72.1% for stage II, 58.0% for stage IIIA, and 48.2% for stage IIIB ( p = 0.002). The 5-year relapse-free survival (RFS) rates were 85.2% for stage IB, 71.2% for stage II, 53.3% for stage IIIA, and 39.2% for stage IIIB ( p < 0.001). A total of 769 cycles of chemotherapy were delivered, and 15 patients experienced grade 3 or higher leukopenia. The most common grade 3 or higher non-hematologic toxicity was nausea/vomiting (11 patients), followed by stomatitis (3 patients). Conclusions Adjuvant chemotherapy with FAM for 6 months for gastric carcinoma indicated comparable RFS and OS with an acceptable toxicity profile.